Anaverse™ Glenoid System and Its Instrumentation

Shoulder Pain Clinical Trial

Official title:

Anaverse™ Glenoid System and Its Instrumentation - Retrospective and Prospective, Non-Controlled Post Market Clinical Follow-Up Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05215600
• Other study ID #: CME2017-11E
• Status: Terminated
• Start date: May 6, 2022
• Est. completion date: April 23, 2024

Study information

• Verified date: May 2024
• Source: Zimmer Biomet
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objectives of this study are to confirm safety, performance and clinical benefits of the Anaverse™ Glenoid System and its instrumentation by analysis of standard scoring systems, radiographs and adverse event records.

Description:

The safety of the system will be assessed by monitoring the frequency and incidence of adverse events.

The performance and clinical benefits will be evaluated by assessment of the overall pain and functional performance, survival, and radiographic parameters of all enrolled study subjects.

The primary endpoint is defined by the survival of the implant system at 2 years which is based on removal or intended removal of the Anaverse™ Glenoid System baseplate and will be determined by using the Kaplan Meier method.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 21
• Est. completion date: April 23, 2024
• Est. primary completion date: April 23, 2024
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patient is 18-75 years of age, inclusive.

• Patient is skeletally mature.

• Patient is capable of understanding the doctor's explanations, following his instructions and is able to participate in the follow-up program.

• Patient must have signed EC-approved informed consent.

• Patient requires a primary reversed total shoulder arthroplasty or a conversion from anatomical to reversed to relieve pain and restore the joint function.

• Patient has adequate quality and quantity of bone stock to support the prosthesis.

• Patient meets at least one of the following indications:

• Advanced wear and tear of the shoulder joint resulting from degenerative, posttraumatic or rheumatoid arthritis

• Conditions consequent to earlier operations

• Omarthrosis or Osteoarthritis

• Rheumatoid arthritis

• Total joint reconstruction following trauma

• Patient has significant shoulder disability due to gross and irreparable rotator cuff deficiency. A functional deltoid muscle is necessary to use the device.

• Patient underwent reverse total shoulder reconstruction with the Anaverse Glenoid System before the date of site initiation.

• Patient has demographic, pre-operative evaluation, operative report and device information available.

Specific inclusion criteria for Conversion from Anatomical to Reversed Configuration:

• Surgery was performed with the Anaverse Glenoid System in a previously available anatomical configuration.

• Irreparable rotator cuff with superior migration of the humeral head, leading to a reduction in sub-acromial space.

• Superior tilt of the Anaverse Glenoid Baseplate not exceeding 15° compared to scapular axis.

• No evidence of mechanical or fixation failure of the Baseplate, TM Pegs or DPSC Screws, obtained pre- or intra-operatively, which would compromise the success of the conversion surgery.

Exclusion criteria:

• Patient is unwilling or unable to give consent or to comply with the follow-up program.

• Patient has any condition which would in the judgment of the Investigator place the patient at undue risk or interfere with the study.

• Patient is known to be pregnant or breastfeeding.

• Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, anticipated to be non-compliant).

• Patient has any physical conditions that would impair adequate implant support and/or prevent the use of an appropriately sized implant.

• Patient has any sign of infection (affecting the shoulder joint or in its proximity).

• Patient has glenoid presenting with large defects due to erosion, which would lead to insufficient bony support or malalignment of the devices.

• Patient is skeletally immature.

• Patient has any sign of neuromuscular compromise (excluding rotator cuff tear).

• Patient has vascular deficiency in the affected limb in sufficient degree to endanger the success of the intervention.

• Patient has absence of musculo-ligamentous supporting structures.

• Patient suffers from joint neuropathy or other conditions that may lead to inadequate skeletal fixation.

• Patient has significant injury to the upper brachial plexus.

• Patient has non-functional deltoid muscle.

Specific exclusion criteria for Conversion from Anatomical to Reversed Configuration:

• Unstable fixation of Baseplate after removal of PE Liner.

• Superior tilt of Baseplate exceeding 15° compared to scapular axis

• Superior malposition of the Baseplate which would prevent correct assembly of the Glenosphere.

• Evidence of mechanical or fixation failure of the Baseplate, TM Pegs or DPSC Screws, obtained pre- or intra-operatively, which would compromise the success of the conversion surgery.

Related Conditions & MeSH terms

• Arthropathy
• Arthroplasty Complications
• Rotator Cuff Injuries
• Shoulder Pain

Intervention

Device:
• Anaverse Shoulder System
Reverse Shoulder Arthroplasty

Locations

Country	Name	City	State
Switzerland	Balgrist University Hospital	Zurich

Sponsors (1)

Lead Sponsor	Collaborator
Zimmer Biomet

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prosthesis survival	The primary endpoint of this study is the survival of the implant (Reversed configuration) after 2 years, which is based on removal of the baseplate and will be determined using the Kaplan-Meier method.	2 years